We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+32.7%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$1.21B
AUM Growth
+$566M
Cap. Flow
+$18.9M
Cap. Flow %
1.56%
Top 10 Hldgs %
61.2%
Holding
106
New
26
Increased
22
Reduced
28
Closed
20

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$20.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$19M
3
NVS icon
Novartis
NVS
+$17.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$11.6M
5
NVO
Novo Nordisk
NVO
+$10.5M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$24.8M
2
ARQL
Arqule Inc
ARQL
+$20.7M
3
GILD icon
Gilead Sciences
GILD
+$13.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 53.1%
2 Miscellaneous 38.29%
3 Technology 6.25%
4 Industrials 0.98%
5 Consumer Discretionary 0.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.6B
$266M 21.95%
+2,800,000
New +$242M
IBB icon
2
PUT
iShares Biotechnology ETF
IBB
$10.5B
$121M 9.93%
+1,000,000
New +$112M
JNJ icon
3
Johnson & Johnson
JNJ
$646B
$64M 5.27%
438,653
+38,653
+10% +$5.24M
BMY icon
4
Bristol-Myers Squibb
BMY
$129B
$58.7M 4.84%
915,000
-194,900
-18% -$11.2M
SNY icon
5
Sanofi
SNY
$103B
$57.2M 4.72%
1,140,000
+440,000
+63% +$20.6M
MRK icon
6
Merck
MRK
$362B
$50.5M 4.16%
581,640
+89,080
+18% +$7.32M
NVO
7
Novo Nordisk
NVO
$191B
$37M 3.05%
1,280,000
+380,000
+42% +$10.5M
GILD icon
8
CALL
Gilead Sciences
GILD
$185B
$32.5M 2.68%
500,000
– –
SGEN
9
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$28.6M 2.35%
+250,000
New +$26.5M
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
$27.3M 2.25%
2,800,320
-130,000
-4% -$1.19M
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$12.7B
$21.3M 1.75%
+251,382
New +$19M
NVS icon
12
Novartis
NVS
$267B
$18.9M 1.56%
+200,000
New +$17.9M
SRPT icon
13
Sarepta Therapeutics
SRPT
$2.18B
$18.1M 1.49%
140,000
-108,038
-44% -$10.9M
VRNT
14
DELISTED
Verint Systems
VRNT
$16.1M 1.33%
570,642
+306,640
+116% +$7.47M
ACAD icon
15
Acadia Pharmaceuticals
ACAD
$4.73B
$15.3M 1.26%
357,000
+267,000
+297% +$11.6M
ALXN
16
DELISTED
Alexion Pharmaceuticals
ALXN
$12.5M 1.03%
115,713
-50,000
-30% -$5.35M
TEVA icon
17
CALL
Teva Pharmaceutical Industries Limited
TEVA
$45.8B
$12M 0.99%
1,220,600
-329,400
-21% -$2.94M
VTRS icon
18
Viatris
VTRS
$19.7B
$11.3M 0.93%
+560,000
New +$10.4M
PTCT icon
19
PTC Therapeutics
PTCT
$5.62B
$10.3M 0.85%
214,736
-95,264
-31% -$4.05M
ASND icon
20
Ascendis Pharma A/S
ASND
$15.8B
$10.3M 0.85%
73,773
– –
QURE icon
21
uniQure
QURE
$3.04B
$10M 0.82%
139,514
-37,986
-21% -$2.09M
MSFT icon
22
Microsoft
MSFT
$3.68T
$9.26M 0.76%
58,741
+5,000
+9% +$735K
BPMC
23
DELISTED
Blueprint Medicines
BPMC
$8.49M 0.7%
106,000
+63,500
+149% +$4.75M
XCUR icon
24
Exicure
XCUR
$8.64M
$8.26M 0.68%
19,259
+1,672
+10% +$684K
ALLT icon
25
Allot
ALLT
$400M
$8.25M 0.68%
970,666
+309,635
+47% +$2.54M
1
2 3 4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q4 2019 Portfolio in Review

As of Q4 2019, Sphera Funds Management held 106 positions worth $1.21B, up 87% from $647M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Sphera Funds Management's Q4 2019 filing shows 26 new, 22 increased, 28 reduced and 20 closed positions. Its largest new stake was BioMarin Pharmaceuticals: 251,382 shares worth $21.3M. The largest sale was Celgene Corp, an estimated $24.8M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 77% a quarter earlier, followed by Miscellaneous and Technology.

  • Sphera Funds Management's largest Q4 2019 buy was BioMarin Pharmaceuticals: 251,382 shares worth $21.3M.
  • Sphera Funds Management added most to Sanofi in Q4 2019, an estimated $20.6M increase.
  • Sphera Funds Management's biggest Q4 2019 reduction was Arqule Inc, cutting an estimated $20.7M.
  • Sphera Funds Management fully exited Celgene Corp in Q4 2019, selling an estimated $24.8M.
  • Sphera Funds Management's ten largest holdings make up 61% of its $1.21B portfolio in Q4 2019.
  • Sphera Funds Management opened 26 new positions and closed 20 in Q4 2019.
  • Sphera Funds Management's portfolio value rose 87% quarter-over-quarter to $1.21B.

Based on Sphera Funds Management's 13F filing for Q4 2019, filed 13 Feb 2020.